GlassScriptPhysician profile
John C Peters
NPI 1073628889
$5,065.22
in general payments reported to CMS, 2019-2025
30 companies · $480 in 2025
The $480 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $670 · 2020: $271 · 2021: $1,249 · 2022: $1,084 · 2023: $609 · 2024: $703 · 2025: $480.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,792.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,792.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,318.42 | 2019-2023 | Xarelto |
| Amgen INC. | $863.80 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $580.91 | 2021-2025 | |
| Abbvie INC. | $486.64 | 2021-2025 | |
| Novo Nordisk INC | $394.93 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Abbott Laboratories | $203.37 | 2019-2025 | Freestyle Libre 3, Aveir, Mitraclip |
| Astrazeneca Pharmaceuticals LP | $156.49 | 2019-2022 | |
| Medtronic, INC. | $126.04 | 2021 | |
| Glaxosmithkline, LLC. | $120.35 | 2022-2025 | Shingrix, Arexvy |
| Kowa Pharmaceuticals America, INC. | $107.33 | 2021-2023 | Livalo |
| Opko Pharmaceuticals, LLC | $81.97 | 2024-2025 | Rayaldee |
| Althera Pharmaceuticals LLC | $72.14 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.42 | 2019-2022 | |
| Pfizer INC. | $60.31 | 2020-2022 | |
| Boston Scientific Corporation | $50.01 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $48.17 | 2019-2021 | |
| Amarin Pharma, INC. | $43.72 | 2021-2022 | |
| Currax Pharmaceuticals LLC | $30.33 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $30.24 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $26.47 | 2024 | |
| Bridgebio Pharma, INC. | $23.86 | 2025 | Attruby |
| Bayer Healthcare Pharmaceuticals INC. | $22.61 | 2023 | |
| Kiniksa Pharmaceuticals International, Plc | $21.98 | 2024 | Arcalyst |
| Mallinckrodt Hospital Products INC. | $20.97 | 2024 | Acthar |
| Lexicon Pharmaceuticals, INC. | $20.24 | 2024 | |
| Rhythm Pharmaceuticals, INC. | $19.94 | 2025 | Imcivree |
| Irhythm Technologies, INC. | $18.98 | 2020 | |
| Corcept Therapeutics | $17.09 | 2022 | |
| Philips North America LLC | $16.64 | 2024 | (Ck4) Mcot |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $12.85 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Peters listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.